

NOV 29 2000

**510(k) Summary****FastPack™ Controls**

---

This summary of 510(k) safety and effectiveness is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92.

---

- |  |   |
|--|---|
| <b>1. Submitter<br/>name, address,<br/>contact</b> | Qualigen, Incorporated<br>2042 Corte del Nogal<br>Carlsbad, CA 92009<br><br>Telephone: (760) 918-9165<br>Fax: (760) 918-9127<br><br>Contact Person: Dorothy Deinzer<br><br>Date Prepared: September 29, 2000                    |
| <hr/>  |   |
| <b>2. Device name</b>                              | Proprietary name: FastPack™ Controls<br><br>Common name: Quality Controls<br><br>Classification Name: Single (specified) Analyte Controls (assayed and unassayed)   |
| <hr/>  |   |
| <b>3. Predicate<br/>device</b>                     | Access® Hybritech® PSA QC   |
| <hr/>  |   |
| <b>4. Device<br/>description</b>                   | <b><i>FastPack™ Controls</i></b><br><br>Quality control material in liquid form, in vials, from which the user can directly remove control. They will be formulated at two levels packaged together as a kit.                   |
| <hr/>  |   |
| <b>5. Intended use</b>                             | The FastPack™ Controls are assayed quality control materials for the verification of the accuracy and precision of the FastPack™ Analyzer system when used for the quantitative determination of PSA in human serum and plasma. |
-

6. **Comparison to Predicate Device**      The following table compares the FastPack™ Controls with the Access® Hybritech™ PSA QC:

Feature	Access® Hybritech® PSA QC	FastPack™ Controls
Intended Use	Access Hybritech PSA QC are tri-level controls intended for monitoring system performance of immunoenzymatic procedures for the quantitative determination of total Prostate Specific Antigen (PSA) using the Access Immunoassay Systems.	Assayed quality control material for the verification of the accuracy and precision of the FastPack™ Analyzer system when used for the quantitative determination of PSA in human serum and plasma.
Analytes	PSA	PSA
Matrix	Bovine Serum Albumin	Bovine serum albumin
Form	Liquid	Liquid
Volume	5 mL	5 mL
Levels	3	2



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration  
2098 Gaither Road  
Rockville MD 20850

NOV 29 2000

Ms. Dorothy Deinzer  
Director of Quality Assurance  
and Regulatory Affairs  
Qualigen, Inc.  
2042 Corte del Nogal  
Carlsbad, California 92009

Re: K003095  
Trade Name: ~~FastPack~~™ Controls  
Regulatory Class: I  
Product Code: JJX  
Dated: September 29, 2000  
Received: October 3, 2000

Dear Ms. Deinzer:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895.


A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

Page 2

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "<http://www.fda.gov/cdrh/dsma/dsmamain.html>".

Sincerely yours,

A handwritten signature in cursive script that reads "Steven Gutman".

Steven I. Gutman, M.D., M.B.A.  
Director  
Division of Clinical Laboratory Devices  
Office of Device Evaluation  
Center for Devices and Radiological Health

Enclosure

## Attachment 4

### Indications for Use Statement

510(k) Number

K003095

Device Name


FastPack™ Controls

Indications for  
Use

The FastPack™ Controls are assayed quality control materials for the verification of the accuracy and precision of the FastPack™ Analyzer system when used for the quantitative determination of PSA in human serum and plasma.

PLEASE DO NOT WRITE BELOW THIS LINE – CONTINUE ON ANOTHER PAGE IF  
NEEDED

Concurrence of CDRH, Office of Device Evaluation (ODE)

  
(Division Sign-Off)  
Division of Clinical Laboratory Devices  
510(k) Number K003095

Prescription Use ☒

(Per 21 CFR 801.109)

OR

Over-The-Counter Use ☐